LAZABEMIDE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C8H10ClN3O.ClH
Molecular Weight	236.098
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.NCCNC(=O)C1=CC=C(Cl)C=N1

InChI

InChIKey=JMFKTFLARGGXCC-UHFFFAOYSA-N

InChI=1S/C8H10ClN3O.ClH/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7931245
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/12359039 | https://www.thepharmaletter.com/article/blow-for-roche-as-phase-iii-tempium-trials-are-discontinued

Lazabemide is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under clinical development against Parkinson's disease, Alzheimer's disease and as an aid to smoking cessation. The development of the drug was discontinued due to liver toxicity.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Monoamine oxidase B 72 Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24012182	Inhibitor 8297		0.091 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Alzheimer’s disease 272 Sources: http://www.europeanneuropsychopharmacology.com/article/S0924-977X(99)80017-0/abstract	Primary	Phase III 656	Unknown Approved Use Unknown
Parkinson's disease 226 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8489205	Primary	Phase III 656	Unknown Approved Use Unknown
Smoking 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12359039	Primary	Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.	1994	7931245
Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy.	1997 Mar	9048767
Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway.	2004 Dec	15545290
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.	2004 Sep	15178694

Patents

Sample Use Guides

In Vivo Use Guide

In clinical trial against Parkinson's disease, lazabemide was administered orally at doses 25-200 mg/day

Route of Administration: Oral

In Vitro Use Guide

Lazabemide inhibited recombinant human MAO-B with IC50 of 0.091 uM.

Name

Type

Language

LAZABEMIDE HYDROCHLORIDE

Official Name

English

LAZABEMIDE MONOHYDROCHLORIDE [MI]

Common Name

English

LAZABEMIDE MONOHYDROCHLORIDE

Common Name

English

LAZABEMIDE HYDROCHLORIDE [USAN]

Common Name

English

RO 19-6327/001

Code

English

RO-19-6327/001

Code

English

LAZABEMIDE HCL

Common Name

English

RO-196327001

Code

English

2-PYRIDINECARBOXAMIDE, N-(2-AMINOETHYL)-5-CHLORO-, MONOHYDROCHLORIDE

Common Name

English

N-(2-AMINOETHYL)-5-CHLORO-2-PYRIDINE-CARBOXAMIDE HYDROCHLORIDE

Systematic Name

English

TEMPIUM

Brand Name

English

LAZABEMIDE HYDROCHLORIDE [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C667